Dan Barouch, MD, PhD (Center for Virology and Vaccine Research, BIDMC) and colleagues reported today in Science two studies of laboratory monkeys that suggest antibodies produced during recovery from COVID-19 provide immunity from the virus, whether triggered by infection or vaccine.
Rutgers Pediatricians discuss in Q&A how parents can help keep up to date with vaccinations during the coronavirus crisis.
To help accelerate discovery of therapeutic antibodies or antiviral drugs for SARS-CoV-2, the virus that causes COVID-19, Lawrence Livermore National Laboratory has launched a searchable data portal to share its COVID-19 research with scientists worldwide and the general public.
An antibody derived from a SARS survivor in 2003 appears to effectively neutralize the coronavirus that causes COVID-19, opening the door for speedy development of a targeted treatment.
David Peabody, PhD, and Bryce Chackerian, PhD, are creating vaccines from particles that are the opposite of Trojan Horses: they look deadly on the outside but are harmless on the inside. Their virus-like particles may rouse the immune system into combatting COVID-19. The idea is to trick the body into believing it’s been infected with a microscopic foe.
Two LLNL biomedical scientists who have worked for more than eight years to develop a tularemia vaccine are part of a three-institution team that has been funded to bring their candidate vaccine to readiness for use
The Stay Home, Work Safe order has been lifted across the state, but with so much uncertainty still lingering around COVID-19, many patients may be wary of attending their much-needed appointments, potentially putting themselves at risk for worsening their condition.
Scientists with UC San Diego’s Jacobs School of Engineering and the Qualcomm Institute have developed a new gene prediction algorithm, called MINING-D, that could help researchers investigate the genetic clues behind the variation of symptoms shown in COVID-19 patients — information that is key to creating a versatile and effective vaccine.
Drug trials and the latest on remdesivir and hydroxychloroquine studies, reports of possible vaccine progress, treating COVID in the ICU, public health policy and research on how the pandemic is progressing, can we safely “re-open,” what interventions have worked, which have not, and what still needs to be done.
A study by researchers at La Jolla Institute for Immunology documents a robust antiviral immune response to SARS-CoV-2 in a group of 20 adults who had recovered from COVID-19. The findings show that the body’s immune system is able to recognize SARS-CoV-2 in many ways, dispelling fears that the virus may elude ongoing efforts to create an effective vaccine.
Research and experts on the symptoms and spread of COVID-19, impact on global trade and financial markets, public health response, search for an effective treatment, and more
The second installment of the series will feature some of Tulane's leading researchers.
Medicine’s great triumph over polio holds out hope we can do the same for COVID-19, two researchers say.
Communities on Facebook that distrust establishment health guidance are more effective than government health agencies and other reliable health groups at reaching and engaging “undecided” individuals, according to a study published today in the journal Nature.
FACULTY Q&AANN ARBOR–In late April, the federal government announced Operation Warp Speed, an aggressive COVID-19 vaccine development program that aims to have at least 300 million doses of vaccine available in the United States by January. Jason Pogue, clinical professor of pharmacy, discusses the feasibility of this aggressive timetable.
A group of the world’s best X-ray science facilities has developed a strategy for cooperatively combating COVID-19.
Repurposing existing medicines focused on known drug targets is likely to offer a more rapid hope of tackling COVID-19 than developing and manufacturing a vaccine, argue an international team of scientists in the British Journal of Pharmacology today.
The research team conducted a prospective cohort study focused on Canadian chiropractors’ websites between July 2016 and April 2019. Researchers revisited all identified websites from 2016 in April 2019 to explore changes to posted vaccination material.
Massachusetts Eye and Ear and Massachusetts General Hospital (MGH), members of Mass General Brigham, today announced progress towards the testing and development of an experimental vaccine called AAVCOVID, a novel gene-based vaccine candidate against SARS-CoV2, the virus that causes COVID-19. The AAVCOVID Vaccine Program is a unique, gene-based vaccine strategy that uses adeno-associated viral (AAV) vector, a clinically established gene transfer technology leveraging the properties of a harmless viral carrier.
Following the recent Coronavirus outbreak, almost three million people have been infected worldwide, whereas the death toll has already passed the 200,000 mark, according to official reports.
As governments from countries including the U.S., Germany, Italy and the U.K., explore the possibility of issuing so-called “immunity passports,” a leading global health and legal scholar warns that such action poses significant practical, equitable, and legal issues. In contrast, if and when a vaccine is developed, vaccination certificates will likely play an important role in ending the pandemic and protecting global health.
The Earle A. Chiles Research Institute is using the protein purification technology from TriAltus Bioscience to purify the spike protein of the COVID-19 virus. The protein will be used to measure the effectiveness of a new DNA vaccine, intended to evoke an immune response against the spike protein.
NIH today announced a new initiative aimed at speeding innovation, development and commercialization of COVID-19 testing technologies, a pivotal component needed to return to normal during this unprecedented global pandemic.
A clinical trial now underway is looking at whether blood plasma donated by people recovered from 2019 coronavirus disease (COVID-19) could be used to treat other people with the pandemic virus.
Amid the rapidly evolving global coronavirus disease 2019 (COVID-19) pandemic that has already had profound effects on public health and medical infrastructure across the globe, many questions remain about its impact on child health.
A new study by epidemiologists at the University of Notre Dame suggests social distancing measures at current levels in many states may need to be maintained until the summer to avoid a potentially deadly resurgence of the coronavirus.
The virus that causes COVID-19 is studded on its exterior with “spike proteins,” a key component in its ability to infect human cells. Two University of Georgia researchers, Rob Woods and Parastoo Azadi, are investigating the proteins and sugars on the surface of the virus with the goal of finding information that could lead to vaccines and therapeutics.
The advance has the potential to eliminate complications that arise from missing doses of life-saving medicines, according to the study published today in Nature Materials, a leading peer-reviewed biomedical research journal.
The COVID-19 pandemic demands action on many fronts, from prevention to testing to treatment. Not content to focus its research efforts on just one, the laboratory of George Church in the Blavatnik Institute at Harvard Medical School and the Wyss Institute for Biologically Inspired Engineering at Harvard University is tackling the problem from seven different angles.
A new study calls into question the reliance on disease-free laboratory mice for testing new influenza (flu) vaccines.
ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR) announced today the program and speakers for Virtual ISPOR 2020.
Three researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have received awards to pursue treatments and vaccines for COVID-19 from the California Institute for Regenerative Medicine, the state’s stem cell agency.
In an unprecedented effort, hundreds of thousands of researchers and clinicians worldwide are locked in a race against time to develop cures, vaccines, and better diagnostic tests for COVID-19, the illness caused by the virus SARS-CoV-2.
患有心脏病和其他基础疾病的人士如果感染COVID-19，可能有发展为重症的高风险。有关这种新型病毒性疾病，目前发表的研究很少，心脏病患者可能会不确定他们是否为保持健康采取正确的做法。为此，Mayo Clinic的心脏病科医生、医学博士Stephen Kopecky就心脏病患者在COVID-19疫情期间需要注意哪些事情发表了看法。
Quienes padecen enfermedades cardíacas y otras afecciones corren más riesgo de enfermar gravemente si llegan a desarrollar la COVID-19. Por ello, los pacientes cardíacos posiblemente se pregunten si están haciendo lo correcto para su salud en este momento, cuando hay pocos estudios respecto a esta nueva enfermedad viral.
المصابون بأمراض القلب والحالات الصحية الكامنة الأخرى أكثر عرضة للمرض الخطير إذا أصيبوا بفيروس كورونا المستجد (كوفيد-19). قد يتساءل مرضى القلب عما إذا كانوا يفعلون ما يجب من أجل صحتهم، في وقت لا يتوفر فيه عن هذا المرض الفيروسي الجديد إلا القليل من الأبحاث.
Pessoas com doença cardíaca e outros problemas de saúde subjacentes correm o risco de ficarem gravemente doentes se contraírem a COVID-19. Pacientes cardíacos podem questionar se estão fazendo as coisas certas para sua saúde em um momento em que há poucas pesquisas disponíveis a respeito dessa nova doença viral.
O SARS-CoV-2, o vírus que causa o COVID-19, continua a se espalhar, levando a mais de 20.000 mortes em todo o mundo em menos de quatro meses. Esforços estão progredindo para desenvolver uma vacina para o COVID-19, mas é provável que isso ainda leve de 12 a 18 meses.
UC San Diego nanoengineers received a Rapid Response Research (RAPID) grant from the National Science Foundation to develop—using a plant virus—a stable, easy to manufacture COVID-19 vaccine patch that can be shipped around the world and painlessly self-administered by patients.
The Weizmann Institute's Prof. Roy Bar-Ziv has demonstrated the self-synthesis and self-assembly of a ribosomal subunit on the surface of a chip. The breakthrough could lead to novel types of vaccines, including for antibiotic-resistant bacteria, or to assembly lines to produce complex molecules for a range of industries.
Researchers from CSIRO, Australia's national science agency, have unveiled a new approach to analysing the genetic codes - or the blueprint - of the SARS-CoV-2 virus that causes COVID-19.
Convalescent plasma therapy for COVID-19 patients — an experimental approach of giving a transfusion of plasma collected from a donor who has recovered from COVID-19 to a patient with an active infection — is the focus of a new two-part research initiative at Penn Medicine. Researchers will first collect plasma from people who have recovered from their infection under a donor research protocol. The second part involves conducting clinical trials to test the safety and efficacy of giving that plasma to moderately and severely ill hospitalized patients.
Southern Research announced today that it has entered into a strategic collaboration with New York-based Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, to support the development of a vaccine, TNX-1800, against the new coronavirus disease, COVID-19, based on Tonix’s proprietary horsepox vaccine platform.
Physicians and scientists at UC San Diego Health have launched a pair of serological tests that will look for novel coronavirus antibodies—evidence in persons tested that they have previously been infected by the viral cause of COVID-19, even if they never experienced tell-tale symptoms.
The lab is responding to the coronavirus crisis by imaging disease-related biomolecules, developing standards for reliable coronavirus testing and enabling other essential research.
Recovery. Reentry. Reopen. Return. A new normal. Faculty experts at DePaul University are available for news media interviews about what comes next — after the COVID-19 pandemic. Does the world return to normal or will there be fundamental changes to how we live our lives, work, and travel; and how we are governed?
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right